Edition:
India

Dechra Pharmaceuticals PLC (DPH.L)

DPH.L on London Stock Exchange

2,954.00GBp
4 Aug 2020
Change (% chg)

12.00 (+0.41%)
Prev Close
2,942.00
Open
2,954.00
Day's High
2,956.00
Day's Low
2,910.00
Volume
166,414
Avg. Vol
278,099
52-wk High
3,090.00
52-wk Low
2,030.00

Select another date:

Thu, Jul 9 2020

BRIEF-Dechra Pharma Says Trading In Year In Line With Management Expectations

* DECHRA PHARMACEUTICALS PLC - TRADING IN YEAR WAS ROBUST AND IN LINE WITH MANAGEMENT EXPECTATIONS

BRIEF-UK competition watchdog gives green light to Dechra, Elanco deal

* UK'S COMPETITION AND MARKETS AUTHORITY SAYS HAS DECIDED, ON INFORMATION CURRENTLY AVAILABLE TO IT, NOT TO REFER FOLLOWING MERGER TO A PHASE 2 INVESTIGATION UNDER PROVISIONS OF ENTERPRISE ACT 2002 Source text for Eikon: Further company coverage: (Reporting By Sinead Cruise)

BRIEF-Dechra Pharma Announces Results Of Placing Of Ordinary Shares

* DECHRA PHARMACEUTICALS - TOTAL OF 5.1 MILLION PLACING SHARES OF EXISTING ISSUED SHARE CAPITAL OF CO, HAVE BEEN PLACED BY INVESTEC BANK

BRIEF-Dechra Pharma Says Trading To Most Likely Be Challenging Until Year End After "Record" March

* CONFIRM THAT OUTLOOK FOR FULL YEAR 2020 IS BROADLY IN LINE WITH MANAGEMENT EXPECTATIONS

BRIEF-Dechra Pharma To Conduct Non-Pre-Emptive Placing Of Up To 5.1 Mln Shares

* DECHRA PHARMA - TO CONDUCT A NON-PRE-EMPTIVE PLACING OF UP TO 5.1 MILLION NEW ORDINARY SHARES

BRIEF-UK's CMA Launches Inquiry Into Dechra Pharma-Elanco Merger

* UK'S CMA - LAUNCH OF MERGER INQUIRY BY NOTICE TO DECHRA PHARMACEUTICALS/ELANCO DEAL ON 20 APRIL 2020 Source text for Eikon: Further company coverage:

BRIEF-UK's CMA Invites Comments On Dechra Pharmaceuticals, Elanco Animal Health

* UK'S CMA INVITES COMMENTS ON ANTICIPATED ACQUISITION BY DECHRA PHARMACEUTICALS PLC OF OSURNIA BUSINESS OF ELANCO ANIMAL HEALTH INCORPORATED

BRIEF-Dechra Acquires Worldwide Rights To Mirataz

* TO BUY RIGHTS TO MIRATAZ FROM KINDRED BIOSCIENCES FOR USD43.0 MILLION AND A ROYALTY ON FUTURE SALES

BRIEF-Kindred Biosciences Announces Mirataz Transaction And Reports Q4 Results

* KINDRED BIOSCIENCES ANNOUNCES MIRATAZ® (MIRTAZAPINE TRANSDERMAL OINTMENT) TRANSACTION AND REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-Dechra Pharma Says Prolonged Interruption In China From COVID-19 Would Lead To Co Being "Out Of Stocks"

* DECHRA PHARMACEUTICALS PLC - HY OPERATING PROFIT 23.3 MILLION STG VERSUS 17 MILLION STG

Select another date: